Maryam Lustberg, Director of Breast Center/Chief Breast Oncology at Yale University School of Medicine, shared a post by Smilow Cancer Hospital on X, adding:
“This Translational Breast Cancer Research Consortium study chaired by Mariya Rozenblit is investigating whether acting on positive ctDNA findings of minimal residual disease changes the trajectory of clinical outcomes in those with history of early stage HR positive BC.
Soon to be open also at Dana Farber, Johns Hopkins, MD Anderson, Georgetown, Montefiore, UPMC!
Low intensity trial – so if you have pts not at these centers, they can still come to the closest center. ”
Quoting Smilow Cancer Hospital’s post:
“Smilow Cancer Hospital is now enrolling patients in a new clinical trial for adults (18+) who have completed treatment for stage IIb or III estrogen receptor–positive breast cancer.
More posts featuring Maryam Lustberg.